<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aim: The liver is the most common site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> but <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> seem to be less common in patients with a chronically liver damage </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of our study was to assess the development of metachronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> in patients affected by HBV or HCV related <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Material of study: We retrospectively evaluated above <z:hpo ids='HP_0000001'>all</z:hpo> the development of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> and the 5-year disease free in 457 patients radically treated for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with healthy liver and in 31 patients radically treated for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> affected by liver damage (HBV or HCV related) </plain></SENT>
<SENT sid="3" pm="."><plain>Results: Overall incidence of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> was 9% (44/488), in particular 3.2% in infected patients and 9.4% in non-infected patients (p= 0.34) </plain></SENT>
<SENT sid="4" pm="."><plain>Our results revealed that there is no statistically significant difference between the number of positive lymph nodes of primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and the number of indifferentiated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in infected compared with non-infected patients (29% vs 34.1% and 9.7% vs 13.6% respectively), and the 5-year disease free is better for infected patients (93% and 80%, p = 0.17) </plain></SENT>
<SENT sid="5" pm="."><plain>Discussion: In infected patients we registered a better crude 5-year disease free interval and a fewer incidence of metachronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This difference is in agreement with other results mentioned in literature </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusion: In the light of the reported data, the authors consider that the recent pathogenetic theory of the "metalloproteinase inhibitor" should be taken in account </plain></SENT>
<SENT sid="8" pm="."><plain>Key words: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e>, <z:hpo ids='HP_0012115'>Hepatitis</z:hpo> <z:hpo ids='HP_0011010'>chronic</z:hpo>, Metachronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, Pathogenesis </plain></SENT>
</text></document>